TOGETHER, WE’RE MAKING A
DIFFERENCE IN CANCER TREATMENT

The treatment landscape is changing almost daily and we’re at the forefront with our innovative immuno-oncology cancer therapies and robust pipeline. Our collaborations, research, and support are leading to exciting new discoveries and an amplified sense of hope for patients.

PIPELINE & RESEARCH

Cancer is relentless—but so are we. Our promise is to be your persistent partner in improving outcomes and outlooks with our advanced immunotherapies and continuous product development.

INTRODUCING PLINABULIN

Plinabulin is a first-in-class stem cell modulator with potential anticancer and chemotherapy-induced neutropenia (CIN) prevention benefits. 

Plinabulin is investigational and not FDA approved.

NEWS & MEDIA

From product development updates to corporate news, find the latest right here.

in the headlines:

FDA grants Plinabulin “Breakthrough Therapy Designation”

COLLABORATIONS

Our relationships with the broader research community strengthen our entire oncology platform and product development strategy. These partnerships are key to our product pipeline growth and continue to offer cost-effective expertise.

John Hopkins
MASS General Hospital
University of Basel
University of Basel

CHANGE THE FUTURE OF CANCER TREATMENT WITH US